甲烯蓝染料在乳腺癌淋巴作图中的药代动力学：在妊娠中应用的意义。
Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancer-implications for use in pregnancy.
机构信息
Department of Internal Medicine, Breast Diagnostic Clinic, Mayo Clinic and Mayo Foundation, Rochester, MN, USA.
出版信息
Am J Surg. 2011 Jan;201(1):70-5. doi: 10.1016/j.amjsurg.2009.03.013.
BACKGROUND
although blue dye is routinely used for lymphatic mapping, it is not used for lymphatic mapping in pregnancy-associated breast cancer, because of concern of fetal risk.
METHODS
to investigate the safety of blue dye for lymphatic mapping in pregnant women, the pharmacokinetics of methylene blue dye were examined in 10 nonpregnant women, and the results were extrapolated to estimate maximal fetal exposure to the dye.
RESULTS
plasma and urine measurements indicated that the dye quickly distributed from the breast injection site to the circulation, with 32% of the total dose excreted in urine within 48 hours. Combined with existing data on organ distribution of methylene blue, the estimated maximal dose to the fetus is 0.25 mg (5% of the administered dose), likely further reduced by other physiologic factors related to pregnancy.
CONCLUSIONS
the analysis suggests that methylene blue dye can be used for lymphatic mapping in pregnancy-associated breast cancer with minimal fetal risk.
背景
尽管蓝色染料通常用于淋巴作图，但由于担心胎儿风险，在妊娠相关性乳腺癌中不使用蓝色染料进行淋巴作图。
方法
为了研究蓝色染料用于孕妇淋巴作图的安全性，对 10 名非孕妇的亚甲蓝染料药代动力学进行了研究，并将结果外推以估计胎儿对染料的最大暴露量。
结果
血浆和尿液测量表明，染料迅速从乳房注射部位分布到循环系统，48 小时内有 32%的总剂量从尿液中排出。结合亚甲蓝器官分布的现有数据，估计胎儿的最大剂量为 0.25 毫克（给予剂量的 5%），可能会因与妊娠相关的其他生理因素而进一步降低。
结论
分析表明，亚甲蓝染料可用于妊娠相关性乳腺癌的淋巴作图，胎儿风险最小。
Zotero 插件